Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-VAD+C Regimen and Autologous Transplant in Mantle Cell Lymphoma
NCT00285389Phase 2Completed
- Sponsor
- French Innovative Leukemia Organisation
- Start
- Feb 2002
- Primary completion
- Dec 2005
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in mantle cell lymphoma (MCL), sponsored by French Innovative Leukemia Organisation. Started Feb 2002; status: completed.
02
Drugs
rituximab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00285389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00285389.